Necrotising enterocolitis in a newborn infant treated with octreotide for chylous effusion: is octreotide safe?

Octreotide is a somatostatin analogue used for treating congenital chylothorax and congenital hyperinsulinism in infants. By increasing splanchnic arteriolar resistance and decreasing gastrointestinal blood flow, octreotide indirectly reduces lymphatic flow in chylous effusions. Splanchnic ischaemia...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Case Rep
Päätekijät: Chandran, Suresh, Agarwal, Arpan, Llanora, Genevieve Villablanca, Chua, Mei Chien
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021135/
https://ncbi.nlm.nih.gov/pubmed/32051156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232062
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia